Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer.

ABSTRACT:

Background

Transmembrane E3 ubiquitin ligase (RNF43) mutations are present in approximately 6-18% of colorectal cancers (CRC) and could enhance Wnt/β-catenin signaling, which is emerging as a promising therapeutic target. This study aims to investigate the clinical and molecular characteristics and potential heterogeneity of RNF43-mutant CRC.

Methods

A total of 78 patients with RNF43-mutant CRC were enrolled from July 2013 to November 2022. Demographic data, clinical characteristics, treatment regimens used, and survival outcomes were collected and analyzed.

Results

Our study uncovered that patients with RNF43 mutations in the N-terminal domain (NTD; n = 50) exhibited shorter overall survival (OS; median months, 50.80 versus n

SUBMITTER: Huang ZY 

PROVIDER: S-EPMC10777808 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature